Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Dose-Escalation Phase 1, Investigator- and Participant-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of LY3532226 in Participants With Obesity

NCT06557356 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT06557356
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06557356 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Dose-Escalation Phase 1, Investigator- and Participant-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of LY3532226 in Participants With Obesity
Lead sponsor
Eli Lilly and Company
Phase
Phase 1
Overall status
Completed
Start date
August 16, 2024
Completion date
December 12, 2025
Enrollment
132 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

obesity